Ilyang Pharmaceutical said on the 6th that it received approval from the Ministery of Food and Drug Safety for the phase 1 clinical trial plan (IND) of the new drug candidate IY-82802, a potassium-competitive acid blocker (P-CAB).
IY-828026 aims to treat gastrointestinal diseases such as erosive and non-erosive reflux esophagitis by suppressing gastric acid secretion. Based on the potential for differentiated efficacy and formulation and the safety results in the nonclinical stage, it is expected to be a next-generation new drug.
The phase 1 clinical trial is expected to enroll 86 participants. In healthy adults, IY-828026 will be administered as single and multiple doses, and its safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) will be evaluated in a randomized, double-blind, partially open-label, placebo- and active-controlled, dose-escalation clinical trial.